Picture of Nick Beckett

Nick Beckett

Managing Partner
Co-Head of the CMS Lifesciences Group

CMS China
Beijing Representative Office
Room 1909, China Youth Plaza
No. 19 Dongsanhuan North Road
Chaoyang District, Beijing 100026
China
CMS Cameron McKenna Nabarro Olswang LLP
Cannon Place
78 Cannon Street
London
EC4N 6AF
United Kingdom
Languages English, French
Dispute Resolution

Nick Beckett is Co-Head of the CMS Lifesciences Group. In this position, he jointly leads an international team of more than 150 specialist lawyers.

Nick Beckett is also the Managing Partner of the Beijing Office and Head of Asia-Pacific IP.  Nick manages a team of dedicated sector specialists covering Lifesciences, Energy, TMC and Financial Institutions across the Asia-Pacific region. Nick is also a Solicitor-Advocate of the English Courts.

Nick has substantial experience in coordinating complex multi-jurisdictional matters, regularly working with colleagues throughout CMS and around the world. His work in the areas of commercial and corporate transactions and disputes, parallel trade, anti-counterfeiting, trade mark and patent opinions and IP infringement particularly spans international borders.

more less

"He has a really sophisticated understanding of life sciences in the Asia-Pacific region. He's very comfortable and savvy talking through the differences in jurisdictions and he has great commercial, regulatory and litigation expertise. He's just a delightful person, really generous and very inspired."

Chambers 2017

‘Dynamic’ practice head Nick Beckett ‘has an unparalleled ability to bring international teams together to deliver the precise expertise that his clients require’

Legal 500

Heavyweight IP, parallel trade and patent litigation capability for an impressive roster of clients.

Legal 500

Nick is recommended as a prominent practitioner in his field in the Global Law Experts 2015 for China, PLC Lifesciences Handbook, Super Lawyers London and the Guide to the World’s Leading Trade Mark Law Practitioners.

Relevant experience

  • One of the world’s leading information technology services companies and successfully defending it in China against a top Chinese state-owned enterprise and its subsidiaries in respect of a management consultancy project and an ERP project that our client implemented for them under a global strategic framework agreement.
  • A world-leading supplier of edible coatings to the pharmaceuticals industry in connection with a patent infringement matter spanning a number of jurisdictions, including China.
  • A leading global bed specialist on the highly sensitive and important employment termination of its former management team in China, including its Managing Director and two senior sales leaders based on unsatisfactory performance and serious wrongdoings.
  • Erbe in the first ever UK patent litigation to deal separately with the issues of infringement and validity coordinating with equivalent litigation in Germany, the US and before the EPO.
  • A Japanese pharmaceutical company in a very significant ICC arbitration, with damages of up to $1 billion, concerning a dispute under a worldwide patent licence agreement in the pharmaceutical sector as a result of the wrongful withdrawal of a licensed pharmaceutical product from the market without consent.
  • Asahi Medical in patent litigation in the UK Patents Court and Court of Appeal for a large Japanese medical device company in connection with their blood filtration technology. This also entailed coordinating concurrent litigation across Europe and liaising with the client's Japanese and European patent attorneys.
  • A leading global pharmaceutical company in a high profile dispute concerning a blockbuster pharmaceutical product. The dispute entailed coordinating litigation in Japan and the UK and jurisdictional issues. Complex pharmaceutical litigation, as well as complicated questions of contract law arose.
  • Takeda on successfully opposing the grant of a competitor’s (Bethesda Pharmaceuticals Inc) European patent at the Opposition Division of the European Patent Office.
  • Quinn Group in connection with a branding dispute regarding the rebranding of the Belfry Hotel as part of the De Vere hotel chain.
  • Sports World International in numerous trade mark litigation matters relating to its own and licensed brands including Kangol, Diadora, Puma and Lonsdale.
more less

Education

2005 - Advocacy Diploma, The College of Law, London

2000 - Intellectual Property Diploma, Bristol University, Bristol

1996 - LPC Distinction, The College of Law, London

1996 - Professional Skills Course, BPP, London

1995 - CPE Distinction, Manchester Metropolitan University, Manchester

1994 - BSc Hons Psychology 1st, University of Manchester, Manchester

more less

Memberships

Honorary Lecturer - China Pharmaceutical University, Nanjing, China

Lecturer - Peking University, China

Lecturer - University of International Business and Economics (UIBE) 

Lecturer - China-EU School of Law, China University of Political Science and Law

Listed Arbitrator at the Beijing International Arbitration Centre (BIAC) and Beijing Arbitration Commission (BAC)

more less
Intellectual Property

Nick Beckett is Co-Head of the CMS Lifesciences Group. In this position, he jointly leads an international team of more than 150 specialist lawyers.

Nick is also the Managing Partner of the Beijing Office and Head of Asia-Pacific IP. Nick manages a team of dedicated sector specialists covering Lifesciences, Energy, TMC and Financial Institutions across the Asia-Pacific region.  Nick is also a Solicitor-Advocate of the English Courts.

Nick has substantial experience in coordinating complex multi-jurisdictional matters, regularly working with colleagues throughout CMS and around the world. His work in the areas of commercial and corporate transactions and disputes, parallel trade, anti-counterfeiting, trade mark and patent opinions and IP infringement particularly spans international borders.

more less

"He has a really sophisticated understanding of life sciences in the Asia-Pacific region. He's very comfortable and savvy talking through the differences in jurisdictions and he has great commercial, regulatory and litigation expertise. He's just a delightful person, really generous and very inspired."

Chambers 2017

‘Dynamic’ practice head Nick Beckett ‘has an unparalleled ability to bring international teams together to deliver the precise expertise that his clients require’

Legal 500

Heavyweight IP, parallel trade and patent litigation capability for an impressive roster of clients.

Legal 500

Nick is recommended as a prominent practitioner in his field in the Global Law Experts 2015 for China, PLC Lifesciences Handbook, Super Lawyers London and the Guide to the World’s Leading Trade Mark Law Practitioners.

Relevant experience

  • A European automotive manufacturer in its IP licensing and actions to protect its portfolio from alleged infringement in many jurisdictions by several companies, including China.
  • Erbe in the first ever UK patent litigation to deal separately with the issues of infringement and validity coordinating with equivalent litigation in Germany, the US and before the EPO.
  • A world leading IT network company on the coordination of enforcement activity against a Chinese trademark infringer.
  • A leading international agrochemical company for the client's Crop Protection Business on patent infringement, anti-counterfeiting, customs and regulatory dispute work, including coordinating with other CMS offices and bringing together a network to service the client's needs.
  • An art tools manufacturer on the strategic restructuring of its trademark portfolio in China and the implementation of further agreements to bolster the value of its rights.
  • A world-leading supplier of edible coatings to the pharmaceuticals industry in connection with a patent infringement matter spanning a number of jurisdictions. This involved coordinating patent litigation and patent prosecution, as well as advising the client on general commercial strategy.
  • A Hong Kong based biotechnology company on a freedom to operate (FTO) search on a number of its core products across Asia-Pacific.
  • BudejovickyMetanskyPivovar in trade mark litigation with Anheuser- Busch relating to use of the term BUDWEISER.
  • A major US pharmaceutical company in disputes with numerous parallel traders.
  • Quinn Group in connection with a branding dispute regarding the rebranding of the Belfry Hotel as part of the De Vere hotel chain.
more less

Education

2005 - Advocacy Diploma, The College of Law, London

2000 - Intellectual Property Diploma, Bristol University, Bristol

1996 - LPC Distinction, The College of Law, London

1996 - Professional Skills Course, BPP, London

1995 - CPE Distinction, Manchester Metropolitan University, Manchester

1994 - BSc Hons Psychology 1st, University of Manchester, Manchester

more less

Memberships

Honorary Lecturer - China Pharmaceutical University, Nanjing, China

Lecturer - Peking University, China

Lecturer - University of International Business and Economics (UIBE) 

Lecturer - China-EU School of Law, China University of Political Science and Law

Listed Arbitrator at the Beijing International Arbitration Centre (BIAC) and Beijing Arbitration Commission (BAC)

more less
Lifesciences

Nick Beckett is Co-Head of the CMS Lifesciences Group. In this position, he jointly leads an international team of more than 150 specialist lawyers.

Nick is also the Managing Partner of the Beijing Office and Head of Asia-Pacific IP. Nick manages a team of dedicated sector specialists covering Lifesciences, Energy, TMC and Financial Institutions across the Asia-Pacific region. Nick is also a Solicitor-Advocate of the English Courts.

Nick has substantial experience in coordinating complex multi-jurisdictional matters, regularly working with colleagues throughout CMS and around the world. His work in the areas of commercial and corporate transactions and disputes, parallel trade, anti-counterfeiting, trade mark and patent opinions and IP infringement particularly spans international borders.

more less

"He has a really sophisticated understanding of life sciences in the Asia-Pacific region. He's very comfortable and savvy talking through the differences in jurisdictions and he has great commercial, regulatory and litigation expertise. He's just a delightful person, really generous and very inspired."

Chambers 2017

‘Dynamic’ practice head Nick Beckett ‘has an unparalleled ability to bring international teams together to deliver the precise expertise that his clients require’

Legal 500

Heavyweight IP, parallel trade and patent litigation capability for an impressive roster of clients.

Legal 500

Nick is recommended as a prominent practitioner in his field in the Global Law Experts 2015 for China, PLC Lifesciences Handbook, Super Lawyers London and the Guide to the World’s Leading Trade Mark Law Practitioners.

Relevant experience

  • Takeda Pharmaceutical Company Limited on its €9.6 billion (debt-free cash free) acquisition of Swiss drug company, Nycomed A/S.
  • A Japanese pharmaceutical company in a very significant ICC arbitration, with damages of up to $1 billion, concerning a dispute under a worldwide patent licence agreement in the pharmaceutical sector as a result of the wrongful withdrawal of a licensed pharmaceutical product from the market without consent.
  • A global pharmaceutical company on its market entry into China including obtaining relevant licence and setting up a compliance program, establishing its branch company in China and preparing and submitting the legal documents for the registration with the local authorities.
  • A world leading gas supplier on its joint medical institution project in China in cooperation with its domestic partner from various perspectives (corporate, compliance, regulatory and commercial).
  • A leading global pharmaceutical company in a high profile dispute concerning a blockbuster pharmaceutical product. The dispute entailed coordinating litigation in Japan and the UK and jurisdictional issues. Complex pharmaceutical litigation, as well as complicated questions of contract law arose.
  • One of the leading traditional Chinese medicine (TCM) companies in China in its management control dispute relating to a joint venture in The Netherlands.
  • Eli Lilly in a leading pharmaceutical parallel trade repackaging case before the CJEU.
  • A global leading medical device company on a strategically important investigation into a compliance breach within their distribution channels in Indonesia and South-East Asia.
  • A Japanese pharmaceutical company on conducting IP due diligence in respect of 2 anti-depressant compounds the subject of a successful world-wide collaboration agreement.
  • A Tianjin-based biotechnology company specialising in novel HIV biologics on international pre-clinical through to Phase III clinical trial development.  Identifying opportunities and facilitating introductions to potential R&D partners in Europe and North America.  Advising on potential entry into Western pharmaceutical markets and the feasibility of deal structures, including the licensing of intellectual property and establishing joint ventures.
more less

Education

2005 - Advocacy Diploma, The College of Law, London

2000 - Intellectual Property Diploma, Bristol University, Bristol

1996 - LPC Distinction, The College of Law, London

1996 - Professional Skills Course, BPP, London

1995 - CPE Distinction, Manchester Metropolitan University, Manchester

1994 - BSc Hons Psychology 1st, University of Manchester, Manchester

more less

Memberships

Honorary Lecturer - China Pharmaceutical University, Nanjing, China

Lecturer - Peking University, China

Lecturer - University of International Business and Economics (UIBE) 

Lecturer - China-EU School of Law, China University of Political Science and Law

Listed Arbitrator at the Beijing International Arbitration Centre (BIAC) and Beijing Arbitration Commission (BAC)

more less

Feed

Show only
15/12/2015
CMS Glob­al Lifes­ci­ences For­um 2015
Shap­ing the fu­ture through in­nov­a­tion and col­lab­or­a­tion
08/01/2018
China Lifes­ci­ences Monthly Up­date – Decem­ber 2017
CF­DA cla­ri­fies the pri­or­it­ised eval­u­ation re­gime, 28 Decem­ber China Food and Drug Ad­min­is­tra­tion ("CF­DA”) is­sued the Opin­ions on En­cour­aging the Pri­or­it­ised Eval­u­ation and Ap­prov­al for Drug In­nov­a­tions (“Opin­ions”) on 28 Decem­ber 2017.
03/06/2014
Won­der and Danger: Asi­an Leg­al Busi­ness - May 2014
13/12/2017
China Monthly TMT Up­date Decem­ber 2017
MIIT re­leased plan to use 3000-5000MHz for 5G The Min­istry of In­dustry and In­form­a­tion Tech­no­logy (“MIIT”) re­leased the plan to use 3000-5000MHz (middle-fre­quency band) for 5G sys­tems on 14 Novem­ber 2017, mak­ing China the first coun­try to re­lease the 5G sys­tem.
01/05/2014
The An­ti­dote - Spring 2014
Tak­ing a look at "pharm­er­ging" mar­kets and the re­sur­gence...
30/11/2017
China Lifes­ci­ences Monthly Up­date – Novem­ber 2017
Trans­ition peri­od for re­cord-fil­ing of clin­ic­al tri­al in­sti­tu­tions for med­ic­al devices, 24 Novem­ber CF­DA is­sued a Cir­cu­lar on Ef­fect­ively Work­ing on the Re­cord-fil­ing of Clin­ic­al Tri­al In­sti­tu­tions for Med­ic­al Devices on 24 Novem­ber 2017.
10/03/2014
De­liv­er­ing Con­sumer Products ex­pert­ise in China
15 Nov 17
We­bin­ar: Cy­ber­se­cur­ity in Asia Pa­cific: What you need...
30/11/2017
China Monthly TMT Up­date Novem­ber 2017
MIIT pub­lishes guide for the de­vel­op­ment of key in­dus­tri­al gen­er­ic tech­no­lo­gies The Min­istry of In­dustry and In­form­a­tion Tech­no­logy (“MIIT”) pub­lished the Guide for the De­vel­op­ment of Key In­dus­tri­al Gen­er­ic Tech­no­lo­gies (“Guide”) on 30 Oc­to­ber 2017.
02/09/2013
In Sci­ence, In Sight: Com­puls­ory phar­ma­ceut­ic­al li­cences...
29/11/2017
MIIT pub­lishes the emer­gency re­sponse plan for cy­ber­se­cur­ity in­cid­ents
The Min­istry of In­dustry and In­form­a­tion Tech­no­logy (“MIIT”) pub­lished the Emer­gency Re­sponse Plan for Cy­ber­se­cur­ity In­cid­ents in Pub­lic Net­works (“Plan”) on 14 Novem­ber 2017. This Plan fur­ther im­ple­ments the gen­er­al prin­ciples set out in the PRC Cy­ber­se­cur­ity.
02/09/2013
In Sci­ence, In Sight: Chin­a's Na­tion­al De­vel­op­ment...
31/10/2017
China Lifes­ci­ences Monthly Up­date - Oc­to­ber 2017
New rules on drug clin­ic­al tri­al in­sti­tu­tions draf­ted, 26 Oc­to­ber China Food and Drug Ad­min­is­tra­tion (“CF­DA”) is­sued Ad­min­is­trat­ive Pro­vi­sions on Clin­ic­al Drug Tri­al In­sti­tu­tions (Draft for com­ment) (the “Draft”) on 26 Oc­to­ber 2017.
25/10/2017
China Monthly TMT Up­date – Oc­to­ber 2017
The US com­mu­nic­ated con­cerns with the PRC Cy­ber­se­cur­ity Law to the WTO  On 25 Septem­ber 2017, the United States com­mu­nic­ated its con­cerns with cer­tain meas­ures that China has ad­op­ted in re­la­tion to the PRC Cy­ber­se­cur­ity Law and the rel­ev­ant im­ple­ment­ing meas­ures.
25/10/2017
CF­DA seek com­ments on the Amend­ments of the Drug Ad­min­is­tra­tion Law...
After the State Coun­cil is­sued the Opin­ions on Deep­en­ing the Re­form of Ex­am­in­a­tion and Ap­prov­al Sys­tem and En­cour­aging In­nov­a­tion of Drugs and Med­ic­al Devices (“Opin­ions”) on 8 Oc­to­ber 2017, the China Food and Drug Ad­min­is­tra­tion ("CF­DA") is­sued the Drug Ad­min­is­tra­tion.